Premium
At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high‐risk leukemias
Author(s) -
Norell Håkan,
Moretta Alessandro,
SilvaSantos Bruno,
Moretta Lorenzo
Publication year - 2013
Publication title -
journal of leukocyte biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.819
H-Index - 191
eISSN - 1938-3673
pISSN - 0741-5400
DOI - 10.1189/jlb.0613312
Subject(s) - nk 92 , immunology , biology , interleukin 21 , context (archaeology) , janus kinase 3 , interleukin 12 , cancer research , immunotherapy , leukemia , cytotoxic t cell , immune system , t cell , in vitro , paleontology , biochemistry
Basic Research Review for Clinicians: Mechanisms underlying the anti‐tumor and anti‐CMV functions of NK cells, and γδ T cells, as the preclinical basis of high risk leukemia treatment, focusing on hematopoietic stem cell transplantation.